For over two decades, investigators at Virginia Commonwealth University (VCU) have made significant contributions to our understanding of drugs of abuse. The interests of these researchers encompass drug synthesis and pharmacokinetic, neurochemical, neurochemical, molecular, behavioral and pharmacological characterization of most classes of abused drugs. While there have always been active collaborations among some of these investigators, the drug abuse research effort at VCU has been enhanced by the creation of the NIDA Center on Drug Abuse Research. The primary objective of the Center is to foster interdisciplinary research on drug abuse at VCU. The Center will continue to provide a mechanism for bringing together scientists from many different disciplines who have had the role for all drug abuse grants at VCU, which includes numerous R01's, NIDA contracts, a training grant, several development of young scientists in drug abuse research. Our success in stimulating collaborative research as well as research projects. The role of the Core is to provide program management and facilitate interaction and cooperation among the participants through its administrative, drug synthesis, shared instrumentation, mouse knock-out facility, and oocyte laboratory. In addition, a Small Grants Program provides a mechanism to attract new drug abuse problems by junior and senior scientists already associated with the Center. Of course, basic research will continue to be the primary focus of the Center. Three Projects are devoted to synthesis of nicotine analogs, pharmacological characterization of nicotine receptor subtypes, and preclinical and clinical studies on nicotine addiction. The remaining six projects address the mechanisms by which cannabinoids produce their acute transduction mechanisms that include both adenylyl cyclase and ion channels, and interactions between the opioid and cannabinoid systems. Finally, the roles of the endogenous nicotine and cannabinoids produce their acute and chronic effects. Efforts are directed toward understanding the nature of ligand-receptor interactions, signal transduction mechanisms that include both adenylyl cyclase and ion channels, and interactions between the opioid and cannabinoid systems. Finally, the roles of the endogenous nicotine and cannabinoid systems in drug dependance, pain perception, convulsions and immune function are being examined in a systematic manner.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
3P50DA005274-18S1
Application #
7288631
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Thadani, Pushpa
Project Start
1988-09-30
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2007-06-30
Support Year
18
Fiscal Year
2006
Total Cost
$363,510
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bagdas, Deniz; Alkhlaif, Yasmin; Jackson, Asti et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72-79
Jackson, Kia J; Muldoon, Pretal P; Walters, Carrie et al. (2016) Neuronal calcium/calmodulin-dependent protein kinase II mediates nicotine reward in the conditioned place preference test in mice. Behav Pharmacol 27:50-6
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Poklis, Justin L; Devers, Kelly G; Arbefeville, Elise F et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14-20
Poklis, Justin L; Nanco, Carol R; Troendle, Michelle M et al. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764-9
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Bagdas, Deniz; Muldoon, Pretal P; Zhu, Andy Z X et al. (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67-72
Wolf, Carl E; Goldstein, Ashley; Poklis, Justin L et al. (2014) Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine. J Clin Lab Anal 28:136-40
Ramesh, Divya; Gamage, Thomas F; Vanuytsel, Tim et al. (2013) Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology 38:1039-49

Showing the most recent 10 out of 106 publications